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COMMENTARY
Commentary on the MID3 Good Practices Paper
Efthymios Manolis1,2*, Jacob Brogren2,3, Susan Cole2,4, Justin L. Hay2,4, Anna Nordmark2,3, Kristin E. Karlsson2,3,
Frederike Lentz2,5, Norbert Benda2,5, Gaby Wangorsch2,6, Gerard Pons2,7, Wei Zhao2,8,9, Valeria Gigante2,10,
Francesca Serone2,10, Joseph F. Standing2,11, Aris Dokoumetzidis2,12, Juha Vakkilainen2,13, Michiel van den Heuvel2,14,
Victor Mangas Sanjuan2,15, Johannes Taminiau2,16, Essam Kerwash2,4, David Khan2,3, Flora Tshinanu Musuamba2,17 and
Ine Skottheim Rusten2,18; on behalf of the EMA Modelling and Simulation Working Group
During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and
simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory
assessment of medicines. In the 2011 EMA – European Federation of Pharmaceutical Industries and Associations (EFPIA)
Workshop on Modelling and Simulation, European regulators agreed to the necessity to build expertise to be able to review
M&S data provided by companies in their dossier. This led to the establishment of the EMA Modelling and Simulation Working
Group (MSWG). Also, there was agreement reached on the need for harmonization on good M&S practices and for continuing
dialog across all parties. The MSWG acknowledges the initiative of the EFPIA Model-Informed Drug Discovery and
Development (MID3) group in promoting greater consistency in practice, application, and documentation of M&S and
considers the paper is an important contribution towards achieving this objective.
CPT Pharmacometrics Syst. Pharmacol. (2017) 6, 416–417; doi:10.1002/psp4.12223; published online 27 June 2017.
COMMENTARY
What the MSWG perceives as a problem with the current
applications of M&S is that they are often dissociated from
clinical decisions on the design and objectives of clinical
trials. Although in areas like pediatric drug development
and dose selection the M&S, the clinical and the statistical
objectives are all considered and taken into account in study
design and analysis; these are otherwise often seen as
standalone applications and reported as such. This ad-hoc
application of M&S has implications for the strength of evi-
dence supporting modeling assumptions and consequently
may limit the weight of M&S in clinical and regulatory decision
making. For instance, sometimes M&S analyses are not well
integrated into a phase III study protocol since the rationale
behind it has not been fully communicated and understood.
Then, the collection of the data may become suboptimal and
it will be hard to answer questions about the influence of
intrinsic or extrinsic factors on exposure and response in
patients. A better alternative is to clearly motivate the analy-
sis, set up objectives that are relevant and understandable
to the whole development team, and to plan the study and
analyses accordingly.
A key element in the MID3 white paper1 is the implementa-
tion strategy, i.e., a strategic plan that closely follows the drug
development steps and lays out the knowledge gaps, the
important questions and how these should be addressed
through model-informed activities across the compound,
mechanism, and disease level. The development of a strategic
plan, as proposed by the MID3 group, is expected to improve
communication between the different scientific disciplines
involved in drug discovery and development and optimize utili-
zation of quantitative tools and study designs. The MSWG
considers that the regulatory review of models as part of Sci-
entific Advice, Paediatric Investigation Plan (PIP), Marketing
Authorisation Application (MAA), and other submissions would
be very much facilitated by having access to the MID3 strate-
gic plan.
Another proposal included in the MID3 paper that is important
is the documentation of assumptions, how they are assessed,
and what impact they have on decisions. The MSWG some-
times finds it challenging to discuss models with other disci-
plines. The modelers are often not well informed to evaluate the
clinical assumptions included in the models. On the other hand,
the clinicians often struggle to understand the mathematical
language describing the clinical assumptions and the clinical
impact of the data/mathematical/statistical assumptions. This
creates a communication gap and unnecessarily prolongs the
integrated discussion needed about how the drug product
should be developed and utilized in the best way.
In the best case, the modeling assumptions can be
assessed by model diagnostics, sensitivity tests, or plain rea-
soning. If this is the case, some level of reassurance can be
provided on the model predictions and inferences. If not, the
uncertainty on the assumptions adds to the overall model
uncertainty. In the end, for those using models in the context of
drug development and evaluation, it is important to manage
uncertainties by evaluating their clinical consequences/impact.
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The assumptions table provided in the MID3 paper provides
a good way to document assumptions, uncertainties, and im-
pact in regulatory submissions. Such a structured approach is
expected to improve the dialog between clinicians, modelers,
and other disciplines.
Another important way to improve communication between
different disciplines is the recommendation on the different
sections of the analysis report. The targeted approach of sec-
tions according to audience (all readers vs. technical) is very
much welcome.
The MID3 paper includes additional comments on practical
aspects of conduct, documentation, and reporting of model-
ing and simulation. The proposals, which will not be elabo-
rated here for the sake of brevity, are recognized by the
MSWG and are clearly an improvement compared to what is
currently seen in submissions.
The MSWG also notes that in the past few years the abun-
dance and the quality (in terms of context of use, adherence
to good practices, and reporting) of M&S in the submissions
have increased. There has also been an increased focus on
the development of good practice documents pertaining to
modeling and simulation (Byon et al., 20132; Dykstra et al.,
20153; Overgaard et al., 20154; Nguyen et al., 20165; Jones
et al., 20156) from specific companies and industry groups
(EFPIA) and professional bodies (ISOP, PSI SIGG); the list is
not exhaustive. In addition, the interplay between modelers
and statisticians (i.e., EMA extrapolation workshop,7 EMA
small population workshop,8 ASA-ISOP statistic and pharma-
cometrics interest group) is gaining momentum. The MSWG
finds these trends encouraging, in the sense that it is indica-
tive that M&S is becoming more integrated within drug devel-
opment. Common themes across all these initiatives are the
improvements in communication and reporting. There is a
desire from MSWG to keep the interaction ongoing with the
MID3 EFPIA group, to initiate bilateral contacts with other
groups developing good practices, and to act as a facilitator
for further development and regulatory implementation of
good modeling practice in general. Through its interaction9
with the US Food and Drug Administration OCP pharmaco-
metrics group, PMDA and Health Canada, the MSWG also
envisages harmonization of good modeling practices across
regulators.
To conclude, the MSWG considers that the MID3 white paper
can potentiate the utility of modeling and simulation in regulatory
review in moving from an ad-hoc problem-solving exercise, as it
is often perceived, to an important source of evidence genera-
tion that influences development and benefit/risk decisions,
labeling, risk management, and is crucial for the product life-
cycle. The MSWG supports the principles included in the paper
and invites other groups developing good practices documents
to actively engage in discussions with regulators.
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